基本信息
views: 0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Research Interests
The Tessier lab aims to develop best-in-class therapeutic antibodies and apply them to address multiple key biomedical challenges:
1. Conformational antibodies that selectively recognize protein aggregates for detecting and treating neurodegenerative disorders
2. Brain-targeted bispecific antibodies for detecting and treating neurological disorders
3. Agonist antibodies that activate T cells for treating cancer
4. Neutralizing antibodies for treating COVID-19 and other infectious diseases
5. Potent antibody-drug conjugates for treating cancer
To accomplish this, we develop next-generation technologies for designing, discovering, engineering, characterizing, formulating and delivering therapeutic antibodies. Our technology development efforts are focused in three main areas:
1. Protein engineering and directed evolution
2. Biomolecular screening and high-throughput characterization
3. Machine learning and computational predictions
Our interdisciplinary research program uses experimental and computational approaches for generating new fundamental insights into protein structure and function, molecular origins of protein-protein interactions, and molecular determinants of key antibody properties (stability, solubility, specificity and affinity). Our development of novel high-throughput screening and machine learning methods is focused on discovering therapeutic antibody candidates with drug-like properties.
The Tessier lab aims to develop best-in-class therapeutic antibodies and apply them to address multiple key biomedical challenges:
1. Conformational antibodies that selectively recognize protein aggregates for detecting and treating neurodegenerative disorders
2. Brain-targeted bispecific antibodies for detecting and treating neurological disorders
3. Agonist antibodies that activate T cells for treating cancer
4. Neutralizing antibodies for treating COVID-19 and other infectious diseases
5. Potent antibody-drug conjugates for treating cancer
To accomplish this, we develop next-generation technologies for designing, discovering, engineering, characterizing, formulating and delivering therapeutic antibodies. Our technology development efforts are focused in three main areas:
1. Protein engineering and directed evolution
2. Biomolecular screening and high-throughput characterization
3. Machine learning and computational predictions
Our interdisciplinary research program uses experimental and computational approaches for generating new fundamental insights into protein structure and function, molecular origins of protein-protein interactions, and molecular determinants of key antibody properties (stability, solubility, specificity and affinity). Our development of novel high-throughput screening and machine learning methods is focused on discovering therapeutic antibody candidates with drug-like properties.
Research Interests
Papers共 68 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Emily K Makowski,Hongwei Chen,Matthew Lambert,Eric M Bennett, Nicole S Eschmann,Yulei Zhang,Jennifer M Zupancic,Alec A Desai,Matthew D Smith,Wenjia Lou,Amendra Fernando, Timothy Tully,
STAR Protocolsno. 1 (2022): 101101
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn